Alnylam Pharmaceuticals (ALNY) to Release Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is projected to announce its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect the company to announce earnings of $1.50 per share and revenue of $1.1250 billion for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, April 30, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm’s quarterly revenue was up 84.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.65) EPS. On average, analysts expect Alnylam Pharmaceuticals to post $7 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $310.58 on Thursday. The stock has a market cap of $41.44 billion, a P/E ratio of 181.63 and a beta of 0.39. The company’s 50-day simple moving average is $322.14 and its 200 day simple moving average is $383.15. Alnylam Pharmaceuticals has a twelve month low of $238.62 and a twelve month high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 2,242 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the transaction, the executive vice president directly owned 24,848 shares in the company, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 6,958 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $2,157,536.64. Following the transaction, the chief executive officer owned 85,662 shares in the company, valued at $26,562,072.96. The trade was a 7.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 38,656 shares of company stock valued at $12,370,696 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $243,000. Geneos Wealth Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 175 shares in the last quarter. Flow Traders U.S. LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $241,000. Daiwa Securities Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 70,300.0% during the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after purchasing an additional 703 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ALNY. HC Wainwright reissued a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Weiss Ratings cut shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 6th. Royal Bank Of Canada lowered their target price on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 20th. Finally, Needham & Company LLC decreased their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $472.78.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.